Starting signal sounded: analytica 2012 to offer Early Bird discount

The starting signal has sounded for analytica 2012 in Munich. Application forms for the 23rd International Trade Fair for Laboratory Technology, Analysis and Biotechnology are available to interested companies. Also, a new offer is being introduced this year: For the first time ever, companies that register by January 31, 2011 will receive a five-percent Early Bird discount on selected stand space. Stand-space allocation for analytica 2012 was also moved forward considerably, i.e. to March 15, 2011.

"Preparations for analytica 2012 are already moving ahead at full speed. New application forms are now available," explains Susanne Grödl, Exhibition Director for analytica at Messe München. "As a result, things are moving along much earlier than in previous years, and we can offer our exhibitors an additional incentive: an Early Bird discount of five percent."

The discount applies to all stand space booked between September 1, 2010 and January 31, 2011, regardless of stand size and type (corner, row or island stand). The offer that is even worthwhile for smaller stands.

"The objective of this campaign is to give exhibitors an incentive to book their stand space early," adds Grödl. "After all, earlier registration allows us to move the entire planning process including visitor advertising considerably forward in time - which is something that exhibitors ultimately profit from."

Companies that do not automatically receive their application forms for the 2012 fair can download them directly at www.analytica.de/en/2012.

Most Popular Now

AstraZeneca amends collaboration with Ironwood for…

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess (linaclo...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

FDA grants Fast Track designation for Farxiga in h…

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk ...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Gene-targeted cancer drugs, slow release overcome …

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, prot...

Educational campaign helps teens and their caregiv…

Teenagers face many challenges, and growing up with a chronic skin disease called atopic dermatitis (AD) can impact the ups and downs and transitions to young adulthood. ...

Study points to new drug target in fight against c…

Researchers have identified a potential new drug target in the fight against cancer. In a study this week in the Proceedings of the National Academy of Sciences, an inter...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...